• 1

    Redd S, Markowitz L, Katz S, 1999. Measles vaccine. Plotkin SA, Orenstein WA, eds. Vaccines. Third edition. Philadelphia: W. B. Saunders, 222–250.

  • 2

    Galazka AM, Robertson SE, Kraigher A, 1999. Mumps and mumps vaccine: a global review. Bull World Health Organ 77 :3–14.

  • 3

    Centers for Disease Control and Prevention, 1998. Measles, mumps, and rubella—vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 47 :1–57.

    • Search Google Scholar
    • Export Citation
  • 4

    Cutts FT, Henderson RH, Clements CJ, Chen RT, Patriarca PA, 1991. Principles of measles control. Bull World Health Organ 69 :1–7.

  • 5

    World Health Organization, 1995. Expanded program of immunization, 1995. Immunization schedules in the WHO European region. Wkly Epidemiol Rec 70 :221–227.

    • Search Google Scholar
    • Export Citation
  • 6

    Peltola H, Heinonen OP, Valle M, Paunio M, Virtanen M, Karanko V, Cantell K, 1994. The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program. N Engl J Med 331 :1397–1402.

    • Search Google Scholar
    • Export Citation
  • 7

    Peltola H, Davidkin I, Paunio M, Valle M, Leinikki P, Heinonen OP, 2000. Mumps and rubella eliminated from Finland. JAMA 284 :2643–2647.

    • Search Google Scholar
    • Export Citation
  • 8

    Centers for Disease Control and Prevention, 1996. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 45 :1–25.

    • Search Google Scholar
    • Export Citation
  • 9

    Takahashi M, 2001. 25 years’ experience with the Biken Oka strain varicella vaccine: a clinical overview. Paediatr Drugs 3 :285–292.

  • 10

    White CJ, Kuter BJ, Hildebrand CS, Isganitis KL, Matthews H, Miller WJ, Provost PJ, Ellis RW, Gerety RJ, Calandra GB, 1991. Varicella vaccine (Varivax) in healthy children and adolescents: results from clinical trails, 1987 to 1989. Pediatrics 87 :604–610.

    • Search Google Scholar
    • Export Citation
  • 11

    Meurice F, De Bouver J-L, Vandevoorde D, Woods S, Bogaerts H, 1996. Immunogenicity and safety of a live attenuated varicella vaccine (Oka/SB Bio) in healthy children. J Infect Dis 174 (suppl 3):S324–S329.

    • Search Google Scholar
    • Export Citation
  • 12

    Arvin A, 2001. Varicella vaccine—the first six years. N Engl J Med 344 :1007–1009.

  • 13

    Vasquez M, LaRussa PS, Gershon AA, Steinberg SP, Freudigman K, Shapiro ED, 2001. The effectiveness of the varicella vaccine in clinical practice. N Engl J Med 344 :955–960.

    • Search Google Scholar
    • Export Citation
  • 14

    National Vaccine Advisory Committee, 1991. The measles epidemic. The problems, barriers and recommendations. JAMA 266 :1547–1552.

  • 15

    World Health Organization, 1999. Measles. Progress towards global control and regional elimination, 1998–1999. Wkly Epidemiol Rec 50 :429–439.

    • Search Google Scholar
    • Export Citation
  • 16

    Arguedas AG, Deveikis AA, Marks MI, 1991. Measles. Am J Infect Control 19 :290–298.

  • 17

    Centers for Disease Control and Prevention, 1989. Mumps—United States, 1985–1988.MMWR Morb Mortal Wkly Rep 38 :101–105.

  • 18

    Centers for Disease Control and Prevention, 1991. Increase in rubella and congenital rubella syndrome—United States, 1988–1990. MMWR Morb Mortal Wkly Rep 40 :93–99.

    • Search Google Scholar
    • Export Citation
  • 19

    Roussey M, Senecal J, Bentejac M-C, Xueref C, 1986. La vaccination triple ROR. Immunol Med 15 :9–15.

  • 20

    Clerc M, 1986. Etude clinique du vaccin ROR triple associé a virus vivants atténués contre la rougeole, les oreillons et la rubéole. Immunol Med 15 :16–18.

    • Search Google Scholar
    • Export Citation
  • 21

    Robertson CM, Bennett VJ, Jefferson N, Mayon-White RT, 1988. Serological evaluation of measles, mumps, and rubella vaccine. Arch Dis Child 63 :612–616.

    • Search Google Scholar
    • Export Citation
  • 22

    Dunlop JM, RaiChoudhury K, Roberts JS, Bryett KA, 1989. An evaluation of measles, mumps and rubella vaccine in a population of Yorkshire infants. Public Health Rep 103 :331–335.

    • Search Google Scholar
    • Export Citation
  • 23

    Samoilovich EO, Kapustik LA, Feldman EV, Yermolovich MA, Svirchevskaya AJ, Zakharenko DF, Fletcher MA, Titov LP, 2000. The immunogenicity and reactogenicity of the trivalent vaccine, Trimovax™, indicated for prevention of measles, mumps, and rubella, in 12-month-old children in Belarus. Cent Eur J Public Health 3 :160–163.

    • Search Google Scholar
    • Export Citation
  • 24

    Osaki T, Nishimura N, Kajita Y, 2000. Experience with live attenuated varicella vaccine (Oka strain) in healthy Japanese subjects; 10-year survey at pediatric clinic. Vaccine 18 :2375–2380.

    • Search Google Scholar
    • Export Citation
  • 25

    Just M, Berger R, Just V, 1986. Evaluation of a combined measles-mumps-rubella-chickenpox vaccine. Dev Biol Stand 65 :85–88.

  • 26

    Berger R, Just M, 1988. Interference between strains in live virus vaccines. II: Combined vaccination with varicella and measles-mumps-rubella vaccines. J Biol Stand 16 :275–279.

    • Search Google Scholar
    • Export Citation
  • 27

    Vesikari T, Öhrling A, Baer M, Delem A, Bogaerts H, Andre FE, 1991. Evaluation of live attenuated varicella vaccine (Oka-RIT strain) and combined varicella and MMR vaccination in 13–17-month-old children. Acta Paediatr Scand 80 :1051–1057.

    • Search Google Scholar
    • Export Citation
  • 28

    Watson BM, Laufer DS, Kuter BJ, Staehle B, White CJ, 1996. Safety and immunogenicity of a combined live attenuated measles, mumps, rubella and varicella vaccine (MMRIIV) in healthy children. J Infect Dis 173 :731–734.

    • Search Google Scholar
    • Export Citation
  • 29

    White CJ, Stinson D, Staehle B, Cho I, Matthews H, Ngai A, Keller P, Eiden J, Kuter B, 1997. Measles, mumps, rubella, and varicella combination vaccine: safety and immunogenicity alone and in combination with other vaccines given to children. Clin Infect Dis 24 :925–931.

    • Search Google Scholar
    • Export Citation
  • 30

    Clements DA, 1996. Modified varicella-like syndrome. Infect Dis Clin North Am 10 :617–629.

  • 31

    White CJ, Kuter BJ, Ngai A, Hildebrand CS, Isganitis KL, Patterson CM, Capra A, Miller WJ, Krah DL, Provost PJ, Ellis RW, Calandra GB, 1992. Modified cases of chickenpox after varicella vaccination: correlation of protection with antibody response. Pediatr Infect Dis J 11 :19–23.

    • Search Google Scholar
    • Export Citation
  • 32

    Peltola H, Heinonen OP, 1986. Frequency of true adverse reactions to measles-mumps-rubella vaccine. A double-bind placebo-controlled trial in twins. Lancet 1 :939–942.

    • Search Google Scholar
    • Export Citation
  • 33

    Decker MD, Edwards KM, 1999. Combination Vaccines. Plotkin SA, Orenstein WA, eds. Vaccines. Third edition. Philadelphia: W. B. Saunders, 508–518.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

IMMUNOGENICITY AND SAFETY OF A VARICELLA VACCINE (OKAVAX™) AND A TRIVALENT MEASLES, MUMPS, AND RUBELLA VACCINE (TRIMOVAX™) ADMINISTERED CONCOMITANTLY IN HEALTHY FILIPINO CHILDREN 12–24 MONTHS OLD

View More View Less
  • 1 Research Institute for Tropical Medicine, Manila, The Philippines, Department of Pediatrics, University of the Philippines, General Hospital, Manila, The Philippines; Aventis Pasteur, Lyon, France

The immunogenicity and safety of Okavax™ varicella vaccine, when administered concomitantly with Trimovax™ measles, mumps, and rubella (MMR) vaccine, were assessed in 300 Filipino children 12–24 months old. Three groups received Okavax only, Trimovax only, or both vaccines concomitantly. In sera obtained six weeks after vaccination, high varicella antibody geometric mean titers (GMTs) (115 and 79.8 mIU/mL, respectively) and seroconversion rates (≥ 91.9%) were similar for Okavax given alone or concomitantly with Trimovax. High MMR GMTs and seroconversion rates (mumps ≥ 94.6%, measles and rubella ≥ 98.6%) were not affected by concomitant administration of Trimovax with Okavax. Solicited local and systemic reactions recorded by parents were slightly more numerous after concomitant administration, but the majority of all reactions were mild and transient. The good tolerance and high immunogenicity observed supports the concomitant administration of Okavax and Trimovax to children in their second year of life to protect against four life-threatening diseases while simplifying childhood immunization programs.

Author Notes

Reprint requests: Salvacion Gatchalian, Research Institute for Tropical Medicine, Filinvest Corporate City, Alabang, Muntilupa, The Philippines, Telephone: 63-2-809-7599, Fax: 63-2-842-2245, E-mail: edsal@impactnet.com.
Save